Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Evaluation of the necessary frequency of blood glucose self-monitoring in type 2 diabetic patients. A prospective, controlled, randomised, multicenter study.
ISRCTN ISRCTN79164268
ClinicalTrials.gov identifier
Public title Evaluation of the necessary frequency of blood glucose self-monitoring in type 2 diabetic patients. A prospective, controlled, randomised, multicenter study.
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis To evaluate the impact of the frequency of blood glucose self-monitoring on glycaemic control (HbA1c and occurrence of hypoglycaemia) of type 2 diabetic patients. Currently there are no general recommendations on the frequency of self blood glucose monitoring in type 2 diabetics treated with a fixed insulin regime or oral antidiabetic medication. The study intends to compare over a follow-up period of 6 month patients with a high frequency of self-monitoring with those with a low frequency. This comparison is done separately for two groups of patients:
1. Treated with a fixed insulin regime
2. Treated with oral antidiabetic drugs only
Satisfaction with the recommended treatment is a secondary endpoint of the study.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Germany
Disease/condition/study domain Type 2 diabetes mellitus
Participants - inclusion criteria 1. Patients treated with a fixed dose of mixture insulin twice a day
2. Patients who are treated with one or more oral antidiabetic drugs
3. From 35 to 80 years
4. Informed consent
5. Type 2 diabetic patients
Participants - exclusion criteria 1. Treatment with multiple insulin injections (more than 2/day)
2. Type 1 diabetic patients
3. Advanced renal insufficiency (known creatinine >2.5 mg/dl)
4. >2 hypoglycaemia with necessary outside help within the last three months
5. Hypoglycaemic shock/hyperosmolaric coma within the last three months
6. Pregnancy
7. Severe impaired vision
8. Communication problems
9. Home care/nursing service
Anticipated start date 01/12/2003
Anticipated end date 01/10/2006
Status of trial Completed
Patient information material
Target number of participants 400 (100 in each group)
Interventions Blood glucose monitoring

1. Patients on insulin mixture:
1.1 Maximum recommendation: every day fasting, every second day before dinner, additional once a profile
1.2 Minimum recommendation: once a week a fasting blood glucose

2. Patients who get an oral antidiabetic:
2.1 Maximum recommendation: every second day a fasting blood glucose, once a week a blood sugar check before dinner
2.2 Minimum recommendation: one fasting blood glucose per week
Primary outcome measure(s) HbA1c six months after start of the study
Secondary outcome measure(s) 1. Hypoglycaemia with necessary outside help
2. Hyperosmolar coma
3. Quality of life
4. Compliance
5. HbA1c after 12 months
Sources of funding Federal Ministry of Education and Research (Bundesministerium Für Bildung und Forschung [BMBF]) - Germany - 01GL0303
Trial website
Publications Results: http://www.ncbi.nlm.nih.gov/pubmed/18769484
Contact name Prof  Werner A.  Scherbaum
  Address Deutsches Diabetes Zentrum an der Heinrich-Heine-Universität
Auf´m Hennekamp 65
  City/town Duesseldorf
  Zip/Postcode 40225
  Country Germany
  Tel +49 (0)2113382-200
  Fax +49 (0)2113369103
  Email scherbaum@ddz.uni-duesseldorf.de
Sponsor Federal Ministry of Education and Research (Bundesministerium Für Bildung und Forschung [BMBF]) (Germany)
  Address Südstrasse 125
  City/town Bonn
  Zip/Postcode 53175
  Country Germany
  Tel +49 (0)2283821202
  Fax +49 (0)2283821257
  Email cornelia.bormann@dlr.de
Date applied 05/09/2005
Last edited 09/09/2008
Date ISRCTN assigned 28/10/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central